Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated lactobacillus rhamnosus X253
- Development stage
- Preclinical
- Lead developer
- Shanghai Amplicon-Gene Bioscience
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Inactivated Lactobacillus rhamnosus X253 is a paraprobiotic (non-viable microbial cell) strain derived from the Lactobacillus rhamnosus species. Unlike live probiotics, this strain is heat-treated to render it inactive while preserving its structural components, such as peptidoglycans and lipoteichoic acids, which retain biological activity. It is primarily developed for its potential to modulate the gut microbiota, strengthen the intestinal epithelial barrier, and exert anti-inflammatory effects. Clinical and preclinical research, often conducted by institutions like Northeast Agricultural University, has explored its efficacy in managing metabolic disorders, including obesity and non-alcoholic fatty liver disease (NAFLD), by regulating lipid metabolism and reducing systemic inflammation.
- Other names
- heat-killed Lactobacillus rhamnosus X253tyndallized Lactobacillus rhamnosus X253inactivated L. rhamnosus X253
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on inactivated lactobacillus rhamnosus X253.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated lactobacillus rhamnosus X253.